Pazopanib in the real-world setting in soft tissue sarcomas: data from the Italian national registry
In this nationwide observational real-world study, the outcomes are similar to those reported in the pivotal trial (PALETTE study). Our study includes a significant number of patients with rare/ultra-rare sarcoma subtypes and underlines possible differences in treatment duration among these histologies.
Authors
- Alessandro Mazzocca
- Simone Celant (ORCID: https://orcid.org/0000-0002-7784-4506)
- Pier Paolo Olimpieri (ORCID: https://orcid.org/0000-0001-7934-9034)
- Paolo G. Casali (ORCID: https://orcid.org/0000-0003-4056-8023)
- Alessandro Comandone (ORCID: https://orcid.org/0000-0003-4677-1807)
- Susanna Di Segni
- Luca Tomassini (ORCID: https://orcid.org/0000-0003-3725-5106)
- Pierluigi Russo (ORCID: https://orcid.org/0000-0003-4881-5703)
- B. Vincenzi
- A. Cortellini
Institutions
- Università Campus Bio-Medico (IT)
- Italian Medicines Agency (IT)
- Ospedale San Giovanni Bosco (IT)
- Campus Bio Medico University Hospital (IT)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
Publication Details
- Journal
- ESMO Open
- Published
- 2024-11-27
- DOI
- https://doi.org/10.1016/j.esmoop.2024.103995
- Citations
- 1
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.42
Funders
- Associazione Italiana di Oncologia Medica
- PharmaMar
- Agenzia Italiana del Farmaco, Ministero della Salute